ADYX Stock Overview

A clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. More details

ADYX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($5)

Latest financial reports are more than a year old

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

Adynxx, Inc. Competitors

DermTech

OTCPK:DMTK.Q

US$35.0

eFFECTOR Therapeutics

OTCPK:EFTR

US$940.0

Plant-Based Investment

OTCPK:CWWB.F

US$27.0

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

Price History & Performance

Summary of share price highs, lows and changes for Adynxx
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.0001
52 Week Low	US$0.000001
Beta	0
1 Month Change	0%
3 Month Change	-99.00%
1 Year Change	n/a
3 Year Change	-99.50%
5 Year Change	n/a
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	ADYX	US Biotechs	US Market
7D	0%	-2.3%	-2.6%
1Y	n/a	-6.3%	24.5%

Return vs Industry: Insufficient data to determine how ADYX performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how ADYX performed against the US Market.

Price Volatility

Is ADYX's price volatile compared to industry and market?
ADYX volatility
ADYX Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	17.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ADYX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine ADYX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2007	n/a	Rick Orr	n/a

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

Adynxx, Inc. Fundamentals Summary

How do Adynxx's earnings and revenue compare to its market cap?
ADYX fundamental statistics
Market cap	US$5.00
Earnings (TTM)	-US$10.51m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is ADYX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ADYX income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$10.51m
Earnings	-US$10.51m

Last Reported Earnings

Sep 30, 2019

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did ADYX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/02 01:49
End of Day Share Price	2025/01/02 00:00
Earnings	2019/09/30
Annual Earnings	2018/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Adynxx, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution